Clik here to view.
Cardiovascular Risk of Hydroxychloroquine in the Treatment of Rheumatoid...
Background/Purpose: Hydroxychloroquine (HCQ) is a commonly used 1st-line disease-modifying antirheumatic drug (DMARD) for patients with rheumatoid arthritis (RA) in the U.S., while methotrexate (MTX)...
View ArticleClik here to view.
A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study of Safety,...
Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a prevalent and morbid condition leading to premature death in 10% of those affected. The TRAIL1 trial was a...
View ArticleClik here to view.
A Prediction Model to Distinguish Patients with Multisystem Inflammatory...
Background/Purpose: Multisystem inflammatory syndrome in children (MIS-C) is a rare consequence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). MIS-C shares features with common...
View ArticleClik here to view.
Association of Limited Health Literacy with Clinical and Patient-Reported...
Background/Purpose: Health literacy (HL) is an important social determinant of health defined as the ability to understand and use health information. Limited HL is associated with worse clinical...
View ArticleCOVID-19 Vaccine in Immunosuppressed Adults with Autoimmune Diseases
Background/Purpose: Immunocompromised conditions and/or a history of autoimmune disease were exclusion criteria of the initial SARS-CoV-2 vaccines clinical trials. We assessed the safety and...
View ArticleAdditional Heterologous versus Homologous Booster Vaccination in...
Background/Purpose: Severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2)-induced coronavirus disease 2019 (COVID-19) has led to exponentially rising mortality, particularly in immunosuppressed...
View ArticleClik here to view.
Immunogenicity of mRNA COVID-19 Vaccines at 4 and 12 Weeks Post Full...
Background/Purpose: Emerging evidence indicates that immunosuppressive therapies may result in reduced immunogenicity –and presumably reduced efficacy- following vaccination with mRNA COVID-19...
View ArticleClik here to view.
Breakthrough COVID-19 Infections Post-vaccination Among Immunocompromised...
Background/Purpose: National U.S. data on breakthrough COVID-19 infection in people with autoimmune or inflammatory rheumatic diseases (AIRD) are limited. Our objective was to assess whether...
View ArticleClik here to view.
Depletion of KLRG1+ T Cells in a First-in-human Clinical Trial of ABC008 in...
Background/Purpose: Inclusion body myositis (IBM), a relentlessly progressive autoimmune skeletal muscle disease, has no effective available pharmacological therapy. A prominent feature of IBM on...
View ArticleClik here to view.
Comparative Safety of Gout “Treat-to-target” and “Usual Care” Treatment...
Background/Purpose: Rheumatology societies recommend serum-urate (SU)-driven treat-to-target (TTT) strategies for the management of gout. However, cardiovascular (CV) safety of urate-lowering therapy...
View ArticleRituximab versus Conventional Therapeutic Strategy for Remission Induction in...
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is an eosinophilic ANCA-associated vasculitis.Glucocorticoids, alone or in combination with cyclophosphamide in severe forms,...
View ArticleClik here to view.
Phase 2 Study Results from a Randomized, Double-blind, Placebo-controlled,...
Background/Purpose: Gout can be effectively managed by inhibiting synthesis of uric acid. Tigulixostat is a novel non-purine selective xanthine oxidase inhibitor which lowers production of uric acid...
View ArticleClik here to view.
Efficacy of Emapalumab, an Anti-IFNγ Antibody in Patients with Macrophage...
Background/Purpose: MAS is a life-threatening complication of rheumatic diseases, occurring most frequently in sJIA. The mainstay of MAS treatment is high dose GCs; however, GCs do not always provide...
View ArticleClik here to view.
SARS-CoV-2 Infections Among Vaccinated Individuals with Rheumatic Disease:...
Background/Purpose: While COVID-19 vaccinations are a critical tool to prevent severe infections, poor immunogenicity in immunocompromised people threatens vaccine effectiveness. We analyzed clinical...
View ArticleClik here to view.
Secukinumab in Giant Cell Arteritis: A Randomized, Parallel-group,...
Background/Purpose: Little is known about glucocorticoid-sparing agents in giant cell arteritis (GCA) except for IL-6 inhibition. Secukinumab (SEC) has shown significant improvements in the signs and...
View ArticleClik here to view.
COVID-19 Vaccine Antibody Responses in Patients Treated with B-Cell Agents...
Background/Purpose: Optimal COVID-19 vaccine responses are necessary to protect against severe infection. Patients with systemic rheumatic diseases (SRD) are at risk for not mounting adequate immune...
View ArticleClik here to view.
Humoral and Cellular Immune Responses to a Second Dose of COVID-19 Vaccine...
Background/Purpose: COVID-19 vaccines have robust immunogenicity in the general population. Data on individuals with immune-mediated inflammatory diseases who are taking immunosuppressants remains...
View ArticleAdditional Heterologous versus Homologous Booster Vaccination in...
Background/Purpose: Severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2)-induced coronavirus disease 2019 (COVID-19) has led to exponentially rising mortality, particularly in immunosuppressed...
View ArticleClik here to view.
Immunogenicity of mRNA COVID-19 Vaccines at 4 and 12 Weeks Post Full...
Background/Purpose: Emerging evidence indicates that immunosuppressive therapies may result in reduced immunogenicity –and presumably reduced efficacy- following vaccination with mRNA COVID-19...
View ArticleClik here to view.
Breakthrough COVID-19 Infections Post-vaccination Among Immunocompromised...
Background/Purpose: National U.S. data on breakthrough COVID-19 infection in people with autoimmune or inflammatory rheumatic diseases (AIRD) are limited. Our objective was to assess whether...
View Article